Drug Profile
Lactic acid - Stayble Therapeutics
Alternative Names: STA 363Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Stayble Therapeutics
- Class Alkalinising agents; Analgesics; Hydroxy acids; Lactates; Small molecules
- Mechanism of Action Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Intervertebral disc degeneration; Intervertebral disc displacement
Highest Development Phases
- Phase II Back pain
- Phase I/II Intervertebral disc displacement
Most Recent Events
- 13 Dec 2023 Updated efficacy data from the phase II STA-02 trial in Back pain released by Stayble Therapeutics
- 14 Nov 2023 Efficacy data and adverse event data from a phase IIb trial in Back pain released by Stayble Therapeutics
- 06 Sep 2023 Stayble Therapeutics completes a phase II STA-02 trial in Back pain in the Netherlands, Russia and Spain (Intraspinal, injection) (NCT04673461)